Sale!

CTNNB1 Gene Mental Retardation Autosomal Dominant Type 19 Genetic Test

4,400 د.إ

-21%

The CTNNB1 gene is associated with a condition known as Mental Retardation, Autosomal Dominant Type 19 (MRD19), a disorder characterized by intellectual disability and potentially other neurological or physical abnormalities. Mutations in the CTNNB1 gene, which plays a crucial role in cell signaling and development, are the underlying cause of this condition. These mutations can disrupt normal brain development, leading to the symptoms observed in affected individuals.

Genetic testing for mutations in the CTNNB1 gene can provide a definitive diagnosis of MRD19. This is particularly important for families seeking to understand the cause of intellectual disability and for guiding potential treatment and management options. The test involves analyzing the DNA to identify mutations in the CTNNB1 gene that are known to be associated with the condition.

At DNA Labs UAE, a specialized genetic test for the CTNNB1 gene mutation is available. The cost of the test is 4400 AED. This testing process is crucial for families with a history of MRD19 or where there is a suspicion of the disorder based on clinical symptoms. A positive test result can help in the planning of educational and developmental support, inform about the risk of recurrence in future pregnancies, and potentially guide research into targeted therapies. DNA Labs UAE provides comprehensive support throughout the testing process, from sample collection to interpretation of results, ensuring that individuals and families receive the information and guidance they need.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

CTNNB1 Gene Mental Retardation Autosomal Dominant Type 19 Genetic Test

At DNA Labs UAE, we offer the CTNNB1 Gene Mental Retardation Autosomal Dominant Type 19 Genetic Test. This test is designed to analyze the CTNNB1 gene for mutations or genetic variants that may be associated with mental retardation, autosomal dominant type 19 (MRD19).

Test Components

The CTNNB1 Gene Mental Retardation Autosomal Dominant Type 19 Genetic Test includes:

  • NGS Technology

Price

The cost of the CTNNB1 Gene Mental Retardation Autosomal Dominant Type 19 Genetic Test is 4400.0 AED.

Sample Condition

We accept the following sample conditions for this test:

  • Blood
  • Extracted DNA
  • One drop of blood on FTA Card

Report Delivery

The report for the CTNNB1 Gene Mental Retardation Autosomal Dominant Type 19 Genetic Test will be delivered within 3 to 4 weeks.

Method

We use NGS (Next-Generation Sequencing) technology to perform the CTNNB1 Gene Mental Retardation Autosomal Dominant Type 19 Genetic Test.

Test Type

The CTNNB1 Gene Mental Retardation Autosomal Dominant Type 19 Genetic Test is specifically designed for neurological disorders.

Doctor

This test is conducted under the supervision of a Neurologist.

Test Department

The CTNNB1 Gene Mental Retardation Autosomal Dominant Type 19 Genetic Test is conducted in our Genetics department.

Pre Test Information

Prior to the CTNNB1 Gene Mental Retardation Autosomal Dominant Type 19 Genetic Test, it is important to provide the clinical history of the patient. Additionally, a genetic counseling session will be conducted to draw a pedigree chart of family members affected with CTNNB1 Gene Mental Retardation Autosomal Dominant Type 19.

Test Details

The CTNNB1 gene is responsible for producing a protein called beta-catenin, which plays a crucial role in cell adhesion, communication, and the regulation of various cellular processes. Mutations in the CTNNB1 gene have been associated with MRD19, a rare genetic disorder characterized by intellectual disability, delayed development, and other neurological abnormalities.

NGS genetic testing is a powerful tool used to analyze an individual’s DNA sequence. It allows for the simultaneous analysis of multiple genes, including the CTNNB1 gene, to identify any mutations or genetic variants that may be present. By performing the CTNNB1 Gene Mental Retardation Autosomal Dominant Type 19 Genetic Test using NGS technology, healthcare professionals can determine if there are any mutations in the CTNNB1 gene that may be causing MRD19. This information is valuable for diagnosing the condition, providing appropriate medical management, and offering genetic counseling to affected individuals and their families.

Test Name CTNNB1 Gene Mental retardation autosomal dominant type 19 Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card o
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Neurological Disorders
Doctor Neurologist
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for CTNNB1 Gene Mental retardation, autosomal dominant type 19 NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with CTNNB1 Gene Mental retardation, autosomal dominant type 19
Test Details

The CTNNB1 gene is responsible for providing instructions for the production of a protein called beta-catenin. This protein plays a crucial role in cell adhesion and communication, as well as in the regulation of various cellular processes.

Mutations in the CTNNB1 gene have been associated with a rare genetic disorder known as mental retardation, autosomal dominant type 19 (MRD19). MRD19 is characterized by intellectual disability, delayed development, and other neurological abnormalities.

NGS (Next-Generation Sequencing) genetic testing is a powerful tool used to analyze the DNA sequence of an individual’s genes. It allows for the simultaneous analysis of multiple genes, including the CTNNB1 gene, to identify any mutations or genetic variants that may be present.

By performing an NGS genetic test on an individual suspected of having MRD19, healthcare professionals can determine if there are any mutations in the CTNNB1 gene that may be causing the disorder. This information can be valuable for diagnosing the condition, providing appropriate medical management, and offering genetic counseling to affected individuals and their families.